ERBB2 and breast cancer: We verified the expression level of PAK5 by using IHC staining in HER2 positive breast cancer patients (n = 58) treated with trastuzumab, and found that patients with high expression of PAK5 were resistant to trastuzumab treatment (Fig. 1A).